10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2021-05-17 (Q1 2021) | Holdings: 126 | Value: $23.1B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seagen Inc. | 28.46% | $6.6B | +7.41% | -3.25% | |||
| BGNE - BeiGene, Ltd. | 17.61% | $4.1B | -24.42% | -10.76% | -59.65% | ||
| INCY - Incyte Corporation | 11.28% | $2.6B | -20.80% | -9.26% | -10.66% | ||
| KOD - Kodiak Sciences Inc. | 6.82% | $1.6B | -95.99% | +3.52% | -92.92% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | 4.69% | $1.1B | +1.46% | -21.35% | -24.55% | ||
| ALXN - Alexion Pharmaceuticals, Inc. | Reduce 54% $(729.0M) | 2.65% | $610.6M | ||||
| NVTA - Invitae Corporation | Add 1% ($3.8M) | 2.61% | $601.8M | -8.00% | -87.49% | ||
| BMRN - BioMarin Pharmaceutical Inc. | 2.48% | $573.1M | -24.96% | -2.39% | +1.02% | ||
| ASND - Ascendis Pharma A/S | 1.98% | $456.3M | +20.62% | -11.44% | -36.30% | ||
| PRLD - Prelude Therapeutics Incorporated | 1.90% | $438.7M | -97.88% | -27.62% | -89.37% | ||
| ABCL - AbCellera Biologics Inc. | 1.54% | $354.9M | -94.04% | -50.55% | -76.29% | ||
| ARGX - argenx SE | Add 10% ($27.5M) | 1.34% | $308.3M | +106.41% | +12.38% | +9.71% | |
| IGMS - IGM Biosciences, Inc. | 1.05% | $242.0M | -98.15% | +9.22% | -76.01% | ||
| MRTX - Mirati Therapeutics, Inc. | 1.05% | $241.5M | -11.25% | -63.09% | |||
| MDGL - Madrigal Pharmaceuticals, Inc. | 0.76% | $175.4M | +104.67% | -39.93% | -50.43% | ||
| AMRN - Amarin Corporation plc | Reduce 5% $(9.6M) | 0.71% | $164.3M | -86.74% | +28.38% | -66.36% | |
| GBT - Global Blood Therapeutics, Inc. | Add 250% ($93.6M) | 0.57% | $131.1M | -27.05% | -25.67% | ||
| BCRX - BioCryst Pharmaceuticals, Inc. | 0.56% | $129.3M | -24.67% | +2.10% | -40.29% | ||
| IMCR - Immunocore Holdings plc | New Purchase | 0.47% | $107.3M | -1.64% | -19.65% | -21.66% | |
| PACB - Pacific Biosciences of California, Inc. | 0.46% | $106.7M | -95.89% | +14.06% | -77.76% | ||
| TIL - Instil Bio, Inc. | New Purchase | 0.42% | $97.7M | -93.13% | -18.14% | -63.86% | |
| TLIS - Talis Biomedical Corporation | New Purchase | 0.42% | $97.3M | -99.03% | -26.21% | -90.00% | |
| HRTX - Heron Therapeutics, Inc. | 0.42% | $97.2M | -86.18% | -23.90% | -74.41% | ||
| CERS - Cerus Corporation | 0.36% | $82.4M | -78.47% | -1.02% | -18.98% | ||
| ALLK - Allakos Inc. | Reduce 2% $(1.3M) | 0.35% | $80.7M | -22.13% | -97.15% | ||
| DBVT - DBV Technologies S.A. | 0.34% | $77.9M | -87.25% | -23.66% | -79.69% | ||
| NRIX - Nurix Therapeutics, Inc. | Add 37% ($20.7M) | 0.33% | $76.3M | -59.12% | +18.12% | -61.50% | |
| KYMR - Kymera Therapeutics, Inc. | 0.33% | $76.1M | -33.39% | +11.93% | -65.12% | ||
| RYTM - Rhythm Pharmaceuticals, Inc. | Add 50% ($24.8M) | 0.32% | $74.0M | +170.24% | -44.70% | -86.12% | |
| INSM - Insmed Incorporated | 0.32% | $73.4M | +167.06% | -12.64% | -23.78% | ||
| APLS - Apellis Pharmaceuticals, Inc. | Add 87% ($33.4M) | 0.31% | $71.8M | -68.55% | +9.65% | -19.15% | |
| NBIX - Neurocrine Biosciences, Inc. | 0.29% | $65.8M | +32.84% | -0.87% | -8.27% | ||
| KRYS - Krystal Biotech, Inc. | Add 9% ($4.7M) | 0.25% | $58.6M | +87.19% | -18.90% | -18.31% | |
| FMTX - Forma Therapeutics Holdings, Inc. | 0.25% | $56.7M | -19.88% | -78.06% | |||
| HZNP - Horizon Therapeutics Public Ltd Co | 0.24% | $55.1M | +10.27% | -5.51% | |||
| BCEL - Atreca, Inc. | 0.23% | $54.2M | -40.02% | -81.71% | |||
| ZYME - Zymeworks Inc. | 0.23% | $54.0M | -61.68% | +7.17% | -82.67% | ||
| ADAP - Adaptimmune Therapeutics plc | 0.23% | $52.2M | -94.22% | -21.94% | -70.95% | ||
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.22% | $51.8M | +95.15% | -14.12% | -42.51% | ||
| RARE - Ultragenyx Pharmaceutical Inc. | 0.22% | $50.6M | -69.10% | -25.57% | -56.68% | ||
| NLTX - Neoleukin Therapeutics, Inc. | 0.20% | $47.0M | |||||
| IMTX - Immatics N.V. | New Purchase | 0.19% | $44.8M | -51.83% | +8.76% | -44.86% | |
| DSGN - Design Therapeutics, Inc. | New Purchase | 0.19% | $43.0M | -84.03% | -33.62% | -52.85% | |
| ACHL - Achilles Therapeutics plc | New Purchase | 0.19% | $42.9M | -51.04% | -82.59% | ||
| MRUS - Merus N.V. | 0.18% | $42.6M | +143.89% | -14.09% | -31.23% | ||
| VSTM - Verastem, Inc. | New Purchase | 0.18% | $42.0M | -79.04% | -13.04% | -60.87% | |
| BCAB - BioAtla, Inc. | 0.18% | $41.9M | -99.11% | -11.93% | -95.02% | ||
| ALT - Altimmune, Inc. | New Purchase | 0.17% | $39.0M | -61.81% | -16.32% | -65.96% | |
| FLGT - Fulgent Genetics, Inc. | New Purchase | 0.17% | $38.7M | -70.80% | +23.11% | -21.81% | |
| PTGX - Protagonist Therapeutics, Inc. | 0.16% | $37.2M | +56.72% | +54.04% | -74.08% | ||
| ALGS - Aligos Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| ATHA - Athira Pharma, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| AXSM - Axsome Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | +65.69% | -65.76% | -47.49% | |
| CCXI - ChemoCentryx, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| FREQ - Frequency Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| OPT - Opthea Limited | Reduce 100% | 0.00% | $0.00 | ||||
| RETA - Reata Pharmaceuticals, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| ALKS - Alkermes plc | Reduce 100% | 0.00% | $0.00 | ||||
| ADCT - ADC Therapeutics SA | Reduce 100% | 0.00% | $0.00 | ||||